[Ip-health] WHA71: KEI intervention on the Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018

Thiru Balasubramaniam thiru at keionline.org
Mon May 21 08:17:06 PDT 2018


https://www.keionline.org/27898

WHA71: KEI intervention on the Preparation for the third High-level Meeting
of the General Assembly on the Prevention and Control of Non-communicable
Diseases, to be held in 2018

--

At the 71st World Health Assembly, KEI will deliver the following
intervention regarding the Preparation for the third High-level Meeting of
the General Assembly on the Prevention and Control of Non-communicable
Diseases, to be held in 2018.

11.7 Preparation for the third High-level Meeting of the General Assembly
on the Prevention and Control of Non-communicable Diseases, to be held in
2018

KEI is concerned that companies selling insulin, drugs and therapies for
cancer have been given a prominent role in limiting the discussion of
measures to address the high costs medicine in connection with the upcoming
High-level Meeting of the General Assembly on the Prevention and Control of
Non-communicable Diseases.

Globally, there is alarm over the soaring costs and high prices of new
drugs, vaccines, and diagnostics, as well as patented gene- and cell-based
therapies. However, these topics are barely addressed in the preparatory
documents. In the recent WHO meeting on partnerships and financing held in
Copenhagen, the meeting was co-sponsored by drug companies and a foundation
funded by insulin manufacturers. Drug companies were described as
“partners” in dealing with access issues, as if everyone is seated in the
same boat, with shared interests.

The WHO Framework of Engagement with Non-State Actors is a reminder of the
risks of collaborations with industry groups, and that seems to have been
largely ignored in the context of the NCD negotiations.

There are many obvious issues relating to the pricing of and access to
drugs and services used to treat non-communicable diseases, which should be
addressed.

Governments do not have workable models for determining when prices for
cancer, heart disease, diabetes and rare diseases are excessive, even
though this is a well known and significant problem that needs to be
addressed.

The issue of inadequate competition for biologic drugs well after patent
expiration needs to be fixed.

Governments need to decide if new cell- and gene- based therapies, such as
autologous T-cell immunotherapy or gene therapies like Luxturna, are
medical procedures that are exempt from patent protection under Article
27(3)(a) of the TRIPS Agreement.

And finally, but critically, we need a path for implementing the delinkage
of R&D incentives from prices.

-- 
Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org


More information about the Ip-health mailing list